With masks on, three feet is just as safe as six feet apart in Massachusetts schools, researchers find miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
BOSTON - As COVID-19 infection rates continue to fall, Massachusetts officials are signaling it s almost time to end remote learning and send all school-aged children back to the classroom. While emerging data suggest young children and schools have not been primary drivers of the COVID-19 pandemic, evidence to guide best practices to prevent the spread of the virus in the school setting has been limited and, as a result, national and international recommendations are inconsistent.
A study led by Beth Israel Deaconess Medical Center (BIDMC) physician-researchers provides new, much-needed data about the optimal physical distancing between students for the prevention of COVID-19 in the school setting. In a retrospective, statewide cohort study, the researchers compared the rates of COVID-19 cases in students and staff in Massachusetts public schools among districts with universal mask mandates but different physical distancing requirements. The team found no substantial diff
Adlai Nortye Announces Formation of its New Scientific Advisory Board
World-leading Experts to Provide Guidance to Advance the Company s Drug Development
News provided by
Share this article
Share this article
HANGZHOU, China, March 7, 2021 /PRNewswire/ Adlai Nortye, a global clinical-stage biopharmaceutical company, today announced the formation of its new Scientific Advisory Board (SAB) comprised of five internationally renowned experts. The SAB includes Ronald M. Evans, PhD (Member of the US National Academy of Sciences, Professor at the Salk Institute and Director of the Salk s Gene Expression Laboratory), Tony Hunter, PhD (Member of the US National Academy of Sciences, Professor of Molecular and Cell Biology at the Salk Institute), Jason Pontin (Investor and former senior partner at Flagship Pioneering), Andrew Zhu, MD, PhD (Professor of Medicine at Harvard Medical School) and Wenle Xia, MD (former faculty member at Duke University).
Share this article
Share this article
MINNEAPOLIS, March 8, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU™ (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay. ExoTRU was developed in collaboration with the Azzi laboratory at the Transplantation Research Center at Brigham and Women s Hospital, Harvard Medical School. The ExoTRU test will be the first ever commercially available test capable of discriminating between types of kidney rejection, providing critical information to assist clinician decision making and optimize patient care. The ExoTRU test is expected to launch in calendar 2021 and will be performed in Exosome Diagnostics CLIA-certified, CAP-accredited laboratory in Waltham, Massachusetts.
New study sheds light on potential pathophysiological mechanism underlying delirium
Delirium, a common syndrome among older adults, particularly in those who have recently undergone surgery, critically ill patients in the ICU, and in older patients with multiple health issues, is a form of acute confusion that is characterized by poor attention, disorientation, impaired memory, delusions, and abrupt changes in mood and behavior.
Moreover, patients who experience delirium are at increased risk of long term cognitive decline. Recently, clinicians and scientists have recognized that delirium is one of the first signs of COVID-19 infection in older patients and that it occurs frequently in patients with severe COVID-19 disease.